Free Trial
NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

Century Therapeutics logo
$0.56 0.00 (-0.28%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.04 (+7.14%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Century Therapeutics Stock (NASDAQ:IPSC)

Key Stats

Today's Range
$0.56
$0.58
50-Day Range
$0.39
$0.60
52-Week Range
$0.34
$3.46
Volume
317,604 shs
Average Volume
475,228 shs
Market Capitalization
$48.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.20
Consensus Rating
Buy

Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

IPSC MarketRank™: 

Century Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Century Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Century Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Century Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Century Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Century Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Century Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.31% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Century Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Century Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.31% of the float of Century Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Century Therapeutics has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Century Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Century Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Century Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,285.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Century Therapeutics is held by insiders.

  • Percentage Held by Institutions

    50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Century Therapeutics' insider trading history.
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Stock News Headlines

Chardan Capital Issues Optimistic Forecast for IPSC Earnings
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Leerink Partnrs Issues Pessimistic Outlook for IPSC Earnings
See More Headlines

IPSC Stock Analysis - Frequently Asked Questions

Century Therapeutics' stock was trading at $1.01 at the beginning of 2025. Since then, IPSC shares have decreased by 44.6% and is now trading at $0.56.
View the best growth stocks for 2025 here
.

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings data on Thursday, May, 15th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of ($0.31) by $1.20. The firm had revenue of $109.16 million for the quarter, compared to analysts' expectations of $45.52 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative trailing twelve-month return on equity of 61.66%.

Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Top institutional shareholders of Century Therapeutics include Acadian Asset Management LLC (0.33%), Charles Schwab Investment Management Inc. (0.31%), Baker BROS. Advisors LP (0.28%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include Versant Venture Capital Vi, L, Brent Pfeiffenberger, Douglas Carr, Gregory Russotti, Adrienne Farid and Luis Borges.
View institutional ownership trends
.

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/15/2025
Today
5/28/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.20
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+650.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$136.67 million
Net Margins
-4,837.73%
Pretax Margin
-4,869.53%

Debt

Sales & Book Value

Annual Sales
$114.90 million
Price / Cash Flow
N/A
Book Value
$3.06 per share
Price / Book
0.18

Miscellaneous

Free Float
79,247,000
Market Cap
$48.25 million
Optionable
Optionable
Beta
1.80
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:IPSC) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners